Goodwin Biotechnology Inc. (GBI) signed their first master supply agreement for commercializing an antibody.

With the development of this new partnership, GBI’s integrated contract development and manufacturing organization (CDMO) biologics services will showcase their expertise in bringing a product from clinical trials through commercial supply while providing manufacturing of both drug substance and drug products.

“This is a major milestone in our journey and a validation of the efforts our team has put into evolving GBI, and this is only the next step of many more exciting accomplishments as we continue our evolution,” said CEO Darrin Schellin.

In a statement, the company said that it is looking forward to expanding its horizons and has set new milestones with its new partnership.

Karl Pinto, chairman of the board at GBI, said, “We have always invested and grown while supporting our clients’ success, and this agreement is a testament to the partnership we have built over many years with this key client.”